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Metadherin (MTDH) and Staphylococcal nuclease
domain containing 1 (SND1) are overexpressed and
interact in diverse cancer types. The structural mech-
anism of their interaction remains unclear. Here, we
determined the high-resolution crystal structure of
MTDH-SND1 complex, which reveals an 11-residue
MTDH peptide motif occupying an extended protein
groove between two SN domains (SN1/2), with two
MTDH tryptophan residues nestled into two well-
defined pockets in SND1. At the opposite side of
the MTDH-SND1 binding interface, SND1 possesses
long protruding arms and deep surface valleys that
are prone to binding with other partners. Despite
the simple binding mode, interactions at both trypto-
phan-binding pockets are important for MTDH and
SND1’s roles in breast cancer and for SND1 stability
under stress. Our study reveals a unique mode of
interaction with SN domains that dictates cancer-
promoting activity and provides a structural basis
for mechanistic understanding of MTDH-SND1-
mediated signaling and for exploring therapeutic
targeting of this complex.
INTRODUCTION
MTDH, also known as metadherin, is overexpressed in a large
spectrum of cancer types, and its elevated levels are associated
with poor prognosis in cancer patients (Sarkar and Fisher, 2013;
Wan and Kang, 2013). Functionally, MTDH has been implicated
in several cancer-related processes, including proliferation, cell
death, invasion, and angiogenesis, and has been linked to mul-
tiple oncogenic pathways such as PI3K/AKT, Wnt/b-catenin,
and NF-kB (Emdad et al., 2013; Wan and Kang, 2013). However,
the mechanism by which MTDH regulates these oncogenic
signaling remains elusive. MTDH was originally identified as an
HIV-induced gene in astrocytes, a membrane protein mediating1704 Cell Reports 8, 1704–1713, September 25, 2014 ª2014 The Authe homing of tumor cells to the lung endothelium, and a lysine-
rich protein associated with tight junctions in prostate epithelial
cells (Lee et al., 2013). No functional domain has been identified
in the MTDH sequence, and it interacts via its unstructured
regions with diverse partners, including PLZF (Thirkettle et al.,
2009), NF-kB (Sarkar et al., 2008), BCCIPa (Ash et al., 2008),
and SND1 (Blanco et al., 2011; Meng et al., 2012; Yoo et al.,
2011). Of note, SND1 possesses tumor-promoting function
similar to that of MTDH (Blanco et al., 2011; Meng et al., 2012;
Wang et al., 2012; Yoo et al., 2011).
Recently, we showed that biochemically identified MTDH
mutants with compromised SND1-binding ability exhibit a
reduced capacity to promote expansion and survival of tu-
mor-initiating cells in diverse subtypes of breast cancer (Wan
et al., 2014). Until now, there has been no understanding of
the structure of MTDH and its binding partners, or how their
structures might affect their interactions and the role of those
interactions in cancer.
SND1 is a multifunctional protein harboring four tandem
repeats of Staphylococcal nuclease (SN)-like domains at the
N terminus (SN1-4), and a fusion tudor and SN domain (TSN5
domain) at the C terminus (Callebaut and Mornon, 1997; Pont-
ing, 1997). It belongs to the oligonucleotide/oligosaccharide
binding fold (OB fold) superfamily consisting of proteins that
participate in DNA/RNA binding via the typical b-barrel of the
OB fold (Theobald et al., 2003). SND1 has been frequently pro-
posed as an essential component of the RNA-induced silencing
complex (RISC) with involvement in miRNA-mediated silencing
(Caudy et al., 2003). It was also shown to have a nuclease activ-
ity against hyperedited miRNA primary transcripts (Scadden,
2005). Structural and biochemical analysis of SND1 suggested
that the N-terminal SN domains, particularly SN3/4, possess
RNA binding and nuclease activity (Li et al., 2008), and the C-ter-
minal TSN5 domain interacts with methylated Lys/Arg ligands
and small nuclear ribonucleoprotein (snRNP) complexes (Shaw
et al., 2007).
SND1 is among the very few members of the OB-fold super-
family that participate in interaction with diverse proteins. It
was initially identified as a cellular component that enhances
the transcription of EBNA-2-activated gene (Tong et al., 1995)thors
and later shown to interact with and modulate a broad spec-
trum of proteins involved in transcription (Leverson et al.,
1998; Paukku et al., 2003; Va¨lineva et al., 2005, 2006; Yang
et al., 2002), including oncogenic transcription factors STAT5,
STAT6, and c-Myb. In recent years, SND1 was identified as a
binding partner of MTDH in multiple types of cancer and has
been shown to be important for cancer cell survival under onco-
genic or chemotherapeutic stresses (Blanco et al., 2011; Meng
et al., 2012; Wan et al., 2014; Yoo et al., 2011). Whether the func-
tion of SND1 in cancer relies on MTDH binding remains unclear.
The range of identified SND1-interacting proteins suggests that
its SN domains have evolved into protein-protein interaction
domains; the mode of interaction, however, remains obscure.
Because both MTDH and SND1 interact with diverse cellular
machineries and signaling proteins and are implicated in multi-
ple cancer-related cellular processes and signaling pathways, it
is likely that MTDH and SND1 enhance malignant features by
coordinating tumor-promoting activities via their multiple inter-
action domains/motifs. The complete lack of structural informa-
tion, however, greatly hinders mechanistic understanding of
the function of the MTDH/SND1 complex, despite the signifi-
cant clinical relevance of both proteins in many types of cancer.
Elucidating the structural basis of MTDH-SND1 interaction
is also crucial for developing new ways of targeting MTDH or
SND1 as a cancer therapeutic strategy. Here, we determined
the high-resolution crystal structure of the MTDH-SND1 com-
plex and revealed a unique interface of MTDH-SND1 interac-
tion that is essential for the tumor-promoting function of this
complex.
RESULTS
Mapping of the Minimal Regions of MTDH and SND1 Is
Required for Their Interaction
The primary sequence analysis of MTDH (residues 1–582) sug-
gested that MTDH is largely unstructured in its entire sequence
except a trans-membrane domain near the N terminus (Fig-
ure S1). Thus, MTDHmight function as a scaffold protein and re-
cruit diverse signaling molecules via peptide motifs throughout
its sequence (Figure 1A). Building on our previous observation
that a MTDH fragment (364–470) harbors the essential region
required for interaction with SND1 (Blanco et al., 2011), we
recently mapped a minimal fragment of MTDH (386–407) within
this region that confers SND1 binding similar to longer fragments
of MTDH (Wan et al., 2014). None of the SND1 domains had
been mapped for specific interaction with protein molecules.
To address this gap, we made a handful of SND1 constructs,
and two gave highly soluble recombinant proteins that harbor
the N-terminal SN1/2 and the C-terminal SN3/4-TSN5 domains
of SND1, respectively (Figure 1A). Using a pull-down assay
with a GST-tagged MTDH (364–582), we showed that the SN1/
2 domains (16–339) of SND1 bind stoichiometrically with
MTDH, whereas the SN3/4-TSN5 domains (340–885) had little
interaction with MTDH (Figure 1B). Further analysis of this inter-
action using biolayer interferometry showed that this interaction
was readily reversible (Figure S2A). The binding affinity between
MTDH and SND1 was determined to be around 0.6 mM by
isothermal titration calorimetry (Figure S2B).Cell ReOverall Structure of the MTDH-SND1 Complex
After extensive effort, cocrystallization of the SND1 SN1/2
domains and synthetic peptides harboring MTDH residues
386–407 failed to yield protein crystals, likely due to the relatively
weak interaction between the two proteins. To stabilize the
complex and facilitate crystallization, we fused the SND1 SN1/
2 domains to MTDH (386–407) via a flexible linker of different
lengths. A variant with a 21-residue linker (STGNASDSSSDSSS
SEGDGTV) yielded diffracting crystals. Although the SN1/2 do-
mains are closely related to the SN3/4 domains, structural deter-
mination by molecular replacement using the structure of SN3/4
(Protein Data Bank [PDB] code: 3BDL) was not successful, likely
due to large diversity of the extended loops emanating from the
OB fold. Finally, the structure was determined by selenium SAD
(single-wavelength anomalous dispersion) phasing and refined
to 2.7 A˚ (Table S1).
Five copies of the MTDH-SND1 fusion proteins were found in
each asymmetric unit that is almost identical (Figure S3A), with
the root-mean-square deviation no more than 0.9 A˚ over 290
residues. The number of MTDH residues with defined electron
density varied slightly in different copies. Nonetheless, residues
393–403 of MTDH were visible in all copies (Figure S3B). Both
SN1 and SN2 exhibit the typical OB fold of Staphylococcal
nuclease (SNase) and were arranged in a central symmetry-
related fashion (Figure 1C), similar to SN3/4 (Figure 1D). Each
SN domain contains a b-barrel (b1-b2-b3-b7-b5) capped by a
three helix bundle (a1-a2-a3) and a short b-hairpin (b4-b8) (Fig-
ure 1C). The MTDH peptide (D393WNAPAEEWGN403) occupies
the shallow groove between SN1 and SN2 domains, with the
two tryptophan residues, W394 andW401, making extensive hy-
drophobic contacts with two well-defined hydrophobic pockets
in SND1.
At the opposite side of the MTDH-SND1 interface, SND1
possesses three extended protruding structural elements (the
b6-b7 hairpin in SN1 and the extended Lb4-a1 loop in both SN1
and SN2), resulting in a spiky surface capable of diverse binding
modes (Figure 1C, right panel). Potential molecules with the
likelihood of binding to this surface include small RNAs, compo-
nents of RISC complex, or transcription factors such as STAT5,
STAT6, and c-Myb that have been previously shown to interact
with SND1 (Leverson et al., 1998; Li et al., 2008; Paukku et al.,
2003; Va¨lineva et al., 2005, 2006; Yang et al., 2002). The SN1/2
domains were previously suggested to participate in DNA/RNA
binding (Li et al., 2008). How the hilly surface contributes to
SND1 function and signaling remains to be determined.
Structural Comparison of SN1/2 with SN3/4 and SNase
Superimposition of the structures of SN1/2, SN3/4 (PDB code:
3BDL), and two copies of SNase (PDB code: 2ENB) reveals
similar structures in b sheets and a helices (Figure 1D), with the
root-mean-square deviation of 2.02, 1.67, and 1.68 A˚ over 268,
123, and 116 residues between SN1/2 and SN3/4, between
SN1 and SNase, and between SN2 and SNase, respectively.
Several loop regions are distinctly different, with varied length
and amino acid sequences (Figures 1D and S4). As shown in
detail later, the elongated Lb2-b3 loop in SN1 is crucial for
mediating MTDH binding. The Lb4-a1 loops in SN1 and SN3 are
significantly longer than those in SNase and adopt differentports 8, 1704–1713, September 25, 2014 ª2014 The Authors 1705
Figure 1. Mapping of SND1-MTDH Interaction and Overall Structure of Their Complex
(A) Illustration of SND1 and MTDH domain structure and motifs with known interaction partners. Soluble SND1 fragments used for studying MTDH binding and
interaction motifs in MTDH are shown below.
(B) Pull-down of SND1 fragments by GST-tagged MTDH (364–582), a fragment recently shown to bind to SND1. Experiments were repeated three times;
representative results are shown.
(C) Overall structure of MTDH-SND1 complex. Two perpendicular views are shown. The SN1 and SN2 domains of SND1 are colored cyan and magenta,
respectively, and MTDH are colored yellow. SND1 is shown in ribbon (left) and surface (right). MTDH is shown in worm (backbone) and cylinder (side chain). See
also Figures S1–S4.
(D) Overlay of the structures of SN1/2 (magenta, in the complex with MTDH), SN3/4 (blue, PDB code: 3BDL), and twomodels of SNase (yellow, PDB code: 2ENB)
in stereo view. The difference in Lb2-b3 loop is emphasized by a dashed circle. See also Figures S1–S4.conformations, likely defining different functionalities. Although
two out of six residues at the SNase active site are retained in
SN3, only one remains the same or similar in SN1 and SN4,1706 Cell Reports 8, 1704–1713, September 25, 2014 ª2014 The Auand none is retained in SN2 (Figure S4). This is consistent with
the previous observation that SN3/4 exhibits low nuclease activ-
ity, whereas SN1/2 augments nuclease activity (Li et al., 2008),thors
Figure 2. MTDH-SND1 Binding Interface
(A) A close-up stereo view of MTDH-SND1 inter-
face. The structure is shown similar to Figure 1A
with the same color scheme, except that the side
chain of SND1 is shown in ball and stick and
colored green. The Lb2-b3 loops from SN3 domain
(light blue) and SNase (yellow) are shown for
highlighting the unique structure of SN1 Lb2-b3 loop
required for MTDH binding.
(B) A close-up view of SN1/2 electrostatic poten-
tial showing the hydrophobic pockets for binding
W394 andW401 of MTDH (left). MTDH is shown in
worm (backbone) and cylinder (side chain) and
colored yellow. The electrostatic potential of SN3/
4 reveals the absence ofW394- andW401-binding
pockets and the positively charged surface unfa-
vorable for binding (right).likely by enhancing substrate binding. These observations
suggest that novel functions have evolved for the SN domains
in SND1, whereas the nuclease activity in these SN folds was
reduced (in SN3/4) or diminished (in SN1/2) during evolution.
MTDH-SND1 Interaction Interface
The fact that MTDH occupies an extended groove between SN1
and SN2 on the back of the hilly surface of SND1 supports the
notion that MTDH might serve as a scaffold signaling protein.
This architecture may allow MTDH to bridge SND1 and other
MTDH-associated signaling complexes without interfering
withmajor binding surfaces of SND1. TheMTDH-SND1 interface
thus provides an important basis for understanding diverse
downstream signaling and their function in cancer.
The interface is dominated by hydrophobic van der Waals
contacts of W394 and W401 in MTDH with two separate, well-
defined hydrophobic pockets in SND1, which are buttressed
by hydrogen bond (H-bond) and salt-bridge interactions at the
periphery (Figure 2A). The hydrophobic pocket for W394 is
formed by residues P39, P43, and P44 in the SN1 Lb2-b3 loop
and the side chains of E247 and F250 on the SN2 a1 helix. The
pocket for W401 is about 15 A˚ away and located between the
a1 and a2 helices from SN2, and contoured by hydrophobic res-
idues L256, H279, I284, and L287 and the carbon chain regions
of residues R255, R259, and N281. At the periphery of the hydro-
phobic pockets near one end of the interface, R327 and R324 inCell Reports 8, 1704–1713, SepSND1 form several H-bond and salt-
bridge interactions with D393 and N395
in MTDH and its backbone carbonyl
group at 392 in two of the five complexes
in the asymmetric unit. In the middle,
R255 in SND1 forms an H-bond interac-
tion with the MTDH backbone at 395,
and, at the other end, a few H-bond and
salt-bridge interactions are formed by
residues and backbone atoms from SN1
a1 helix and SN2 b5 strand with MTDH
residues, E400 and N403.
The interface for MTDH binding in
SND1 is highly unique and present onlyin SN1/2 (Figure 2B). The well-defined hydrophobic pockets for
W394 and W401 are clearly shown by the surface contour of
SN1/2 with electrostatic potential, but are absent in SN3/4.
The surface between the two hydrophobic pockets in SN1/2
is basic, which, in part, favors the electrostatic interaction with
E400, but is not ideal for interaction with nonpolar residues
(A396PA398) between W394 and W401. This likely explains the
relatively weak interaction between SND1 and MTDH and the
fast off-rate of this interaction (Figure S2). Unlike SN1/2, the pro-
tein groove between SN3 and SN4 is largely basic, underlying
another structural feature of SN3/4 that disfavors MTDH binding.
Furthermore, the proline residues in the SN1 Lb2-b3 loop lining the
pocket for W394 are all absent in SN3 or SNase (Figures 1D and
S4), further defining the binding specificity of SN1/2 for MTDH.
Identification of MTDH and SND1 Mutants Deficient in
Binding
To gain insight into how the interface characterized above
contributes to MTDH-SND1 interaction, we next performed
structure-guided mutagenesis studies. The structure suggests
that the van der Waals hydrophobic contacts made by MTDH
W394 and W401 might play a dominant role in SND1 binding.
Consistent with this notion, mutating either of the two tryptophan
residues to a much smaller residue alanine (W394A, W401A) or
a negatively charged residue aspartate (W394D, W401D) abol-
ished or significantly reduced the interaction between SND1tember 25, 2014 ª2014 The Authors 1707
Figure 3. Identification of MTDH and SND1 Mutants Deficient in Binding
(A) In vitro pull-down of SND1 (16–339) by GST-tagged MTDH (364–582) harboring WT or mutant sequence. The proteins bound to GS4B were examined on
SDS-PAGE and visualized by Coomassie blue staining.
(B) In vitro pull-down of WT and mutant SND1 (16–339) by GST-tagged MTDH (364–582). The bound proteins were examined as in (A). For both (A) and (B),
experiments were repeated three times; representative results are shown. The normalized percentage of binding was averaged from three experiments;
mean ± SEM was shown below the data.
(C) HEK293T cells were transfected with human HA-SND1, WT Myc-MTDH, or Myc-MTDH with indicated single point mutation. Lysates were immunoprecip-
itated with anti-HA antibody and immunoblotted with the indicated antibodies.
(D) HEK293T cells were transfected with humanMyc-MTDH, WT HA-SND1, or mutant HA-SND1 with indicated single point mutations or deletions. Lysates were
immunoprecipitated with anti-Myc and immunoblotted with the indicated antibodies.(16–339) and MTDH (364–582) in vitro (Figure 3A). The W/ A
mutants exhibited stronger defects than the W / D mutants,
suggesting that the MTDH-SND1 interaction is largely dictated
by van der Waals contacts. The more severe defects of W394A
compared to W401A likely reflect the different flexibility of
the two SND1 pockets. Residues lining the pocket for W401
could adopt multiple rotamer conformations, which might
partially compensate the W401A mutation for interaction with
this pocket. In contrast, the binding pocket for W394 is largely
conferred by three rigid proline residues and thus could barely
compensate the W394A mutation. The MTDH mutations at the
periphery interface (N395A, E400A, E400R, N403A), which are
expected to disrupt H-bond or salt-bridge interactions, had
very little effect, similar to the mutation outside the interface
(D389R) (Figure 3A). These results showed that individual
H-bonds make minor contributions to the MTDH-SND1 interac-
tion and van der Waals contacts play a dominant role in this
interaction.
Several SND1 mutations at the interface that disrupt MTDH
binding were also identified. Changes made to the SND1 hydro-
phobic pockets, including R255E, F250A, and deletion in the1708 Cell Reports 8, 1704–1713, September 25, 2014 ª2014 The AuSN1 Lb2-b3 loop (D39-43), almost completely abolished MTDH
binding (Figure 3B). In addition to perturbing the van der Waals
contacts with W401, R255E might also affect its H-bond interac-
tion with the MTDH backbone (Figure 2A). The effect of D39-43
further supports the role of these residues for MTDH binding,
which are unique to the SN1 Lb2-b3 loop (Figures 2 and 3B).
The R324E mutation significantly weakened the MTDH binding,
likely by introducing a repulsive charge-charge contact with
D393 in MTDH. A different mutation to this residue, R324A,
barely affected MTDH binding, similar to the mutation outside
the interface, R316E.
We further examined how the MTDH and SND1 mutations
identified at this interface affected the interaction of full-length
proteins in mammalian cells. Full-length HA-tagged SND1 was
coexpressed with full-length Myc-tagged wild-type (WT) or
mutant MTDH in HEK293T cells and cell lysates were subjected
to anti-HA immunoprecipitation for SND1 pull down. Consistent
with in vitro observations (Figure 3A), WTMTDH, but not mutants
W394A, W394D, or W401A, was pulled down along with HA-
SND1 (Figure 3C, in red). MTDH mutation W401D significantly
reduced the binding (Figure 3C, in blue), whereas otherthors
Figure 4. Mutations in MTDH and SND1-
Binding Residues Impair Tumor-Promoting
Function
(A) Lysates from PyMT;Mtdh/ tumor cells re-
constituted with vector control, WT or mutant
murine MTDH were immunoprecipitated with anti-
MTDH antibody and immunoblotted for indicated
proteins. Note all amino acid annotations are
based on human MTDH. W394 and W401 of hu-
man MTDH correspond to W391 and W398 in
murine MTDH, respectively.
(B) Mammosphere assays were performed
with PyMT;Mtdh/ tumor cells reconstituted with
indicated MTDH constructs.
(C–E) In vivo tumor formation (C for tumor inci-
dence; D and E for tumor volumes) was performed
at limiting numbers using PyMT;Mtdh/ tumor
cells reconstituted with indicated WT or mutant
MTDH.
(F) Lysates from SND1-KD PyMT;Mtdh+/+ tumor
cells reconstituted with vector control, WT, or
mutant shRNA-resistant murine SND1 were
immunoprecipitated with anti-MTDH antibody and
immunoblotted for indicated proteins.
(G) Mammosphere assays were performed with
SND1-KD PyMT;Mtdh+/+ tumor cells reconstituted
with vector control or indicated SND1 constructs.
(H and I) Mammary tumor incidence (H) and tumor
growth curve (I) after orthotopic transplantations
of SND1-KD PyMT;Mtdh+/+ tumor cells recon-
stituted with indicated constructs.
Statistics: (B, G, and I) Student’s t test. Data repre-
sent mean ± SEM. (C) Limiting dilution analysis. (D
andE)Mann-Whitneytest. (H)Chi-square test. ***p<
0.001, **p < 0.01, *p < 0.05. See also Figure S5.mutations, including the negative control D389R, a mutation
located outside the MTDH-SND1 interface, did not affect the
interaction (Figure 3C). Likewise, the SND1 mutations that
affected MTDH binding in vitro also affected the binding of full-
length proteins in vivo to similar levels. Both WT HA-SND1 and
the negative control mutant, HA-SND1 R316E, bound readily
with Myc-MTDH, whereas other mutations, D39-43, F250A, or
R255E, nearly completely abolished MTDH binding, and R324E
significantly reduced the binding (Figure 3D).
The similar results of in vitro and in vivo studies of MTDH-
SND1 interactions strongly suggest that the MTDH-SND1
interface characterized above dictates the interaction of the
full-length MTDH and SND1 in mammalian cells. This allowed
us to further define the role of this interface in controlling the
function of MTDH and SND1 in cancer promotion.
MTDH Mutants Deficient in SND1 Binding Had Reduced
Protumorigenic Activities
We recently demonstrated an essential role of MTDH in regu-
lating mammary tumorigenesis (Wan et al., 2014). In particular,
genetic deletion ofMtdh in mice impairs the tumor-initiating po-
tential of mammary epithelial cells transformed by diverse onco-
genes (PyMT, Wnt, ErbB2) or carcinogen stimuli, and this defect
can be readily rescued by reintroducing MTDH into Mtdh-
knockout (Mtdh/) tumor cells by lentiviral transduction (Wan
et al., 2014). To test whether interacting with SND1 is importantCell Refor the tumor-initiating effect of MTDH, murine WT or mutant
MTDH (W394A or W401A, corresponding mutations in mouse
are W391A, W398A) was stably expressed in mammary tumor
cells derived from PyMT;Mtdh/ mice. The MTDH mutants
W394A or W401A completely lost the ability to interact with
SND1 (Figure 4A), suggesting that the SND1-interacting residues
of MTDH are conserved between mouse and human. In vitro
mammosphere formation assays showed that PyMT;Mtdh/
tumor cells reconstituted with mutant MTDH formed a signifi-
cantly lower number of spheres compared to those reconstituted
with WT MTDH (Figure 4B). To examine how MTDH mutations
affect tumor formation in vivo, we orthotopically transplanted
PyMT;Mtdh/ tumor cells into the mammary fat pads of
WT recipient mice. We found that PyMT;Mtdh/ tumor cells
reconstituted with mutant MTDH contained substantially fewer
tumor-initiating cells as revealed by reduced tumor incidence
(Figure 4C) when a limited number of cells were injected. Further-
more, the size of tumors formed by PyMT;Mtdh/ tumor cells
reconstituted with mutant MTDH was much smaller than
observed with WT MTDH (Figures 4D and 4E). Staining of Ki67
(Figure S5A) and cleaved caspase-3 (Figure S5B) was performed
on these established tumors to examine their proliferation and
apoptosis indices, respectively, and we did not observe signifi-
cant differences across different groups. These results demon-
strate that the interaction between MTDH and SND1 is essential
for the protumorigenic activity of MTDH, and that this interactionports 8, 1704–1713, September 25, 2014 ª2014 The Authors 1709
Figure 5. MTDH Interaction Protects SND1 from Heat Shock Stress-Induced Degradation
(A) HEK293T cells were transfected with HA-SND1 together with either empty vector control or indicated WT or mutant Myc-MTDH constructs. Two days
postinfections, cells were treated under heat shock conditions, and lysates were immunoblotted for indicated proteins. b-actin was used as loading control.
Representative results of three independent experiments are shown.
(B) The proposedmechanism ofMTDH andSND1 in oncogenic signaling as a scaffold and amultidomain interacting protein, respectively, are illustrated using the
structural model of the full-length MTDH-SND1 complex, modeled based on crystal structures of the MTDH (393–403)-SND1 (16–339) complex and the SN3/
4-TSN5 domains of SND1 (PDB code: 3BDL).contributes predominantly to tumor initiation, consistent with our
recent findings (Wan et al., 2014).
SND1 Mutants Deficient in MTDH Binding Were Inactive
in Tumor Promotion
The well-defined pockets in SND1 for MTDH binding and the
role of this interaction in tumor initiation suggest that the protein
pockets in SND1 represent a therapeutic target for cancer. We
recently demonstrated that knockdown (KD) of SND1 impairs
the tumor-initiating activities of PyMT/Mtdh+/+ tumor cells, sup-
porting a tumor-promoting role of SND1 (Wan et al., 2014). In
thecurrent study,a small hairpinRNA (shRNA)-resistant construct
of WT ormutant SND1 (F250A or R255E) was stably expressed in
SND1-KD PyMT/Mtdh+/+ tumor cells, and their effects on tumor
initiating activities were tested in vitro and in vivo. The SND1 mu-
tations nearly completely abolished the MTDH interaction (Fig-
ure 4F). SND1 mutants barely increase the number of spheres
formed in the in vitro mammosphere assays, whereas WT SND1
increases the sphere numbers by more than 2-fold compared to
controls (Figure 4G). After transplantation of cells into mammary
fatpadsof recipientmice,WTSND1markedlyboosted tumor initi-
ation and tumor growth as reflected by the increased tumor inci-
dence and total tumor burden, whereas SND1mutants exhibited
very minor effects (Figures 4H and 4I). These results further
support our conclusion that the interaction between MTDH and1710 Cell Reports 8, 1704–1713, September 25, 2014 ª2014 The AuSND1 is important for tumor promotion, and that both MTDH-
binding pockets in SND1 are crucial for this activity.
MTDH Mutants Deficient in SND1 Binding Failed to
Stabilize SND1 under Stress
Our recent studies suggested that MTDH plays a key role in
enhancing the stability of SND1 protein under stress conditions
(Wan et al., 2014), which may contribute to the prosurvival
role of SND1 in cancer cells under oncogenic or other stresses
(Gao et al., 2010; Sundstro¨m et al., 2009; Weissbach and Scad-
den, 2012). To further substantiate this conclusion, we examined
the effects of MTDH mutations on the cellular stability of SND1
during heat shock, a condition under which SND1 is important
for cellular survival (Gao et al., 2010; Weissbach and Scadden,
2012). When overexpressed alone, the cellular level of HA-
SND1 was rapidly reduced at 45C, with a half-life of around
30 min (Figure 5A). Coexpression with WT Myc-MTDH
augmented the cellular stability of HA-SND1 at 45C, with the
half-life extended beyond 3 hr, whereas coexpression of either
MTDH mutants, W394A and W401A, failed to stabilize HA-
SND1 during heat shock (Figure 5A). This result supports the
role of MTDH-SND1 interaction in promoting the cellular stability
of SND1, consistent with our recent observation that the protein
levels of MTDH and SND1 are positively correlated in human
breast cancers (Wan et al., 2014).thors
DISCUSSION
MTDH has gained increasing interest in recent years given its
broad implication in diverse cancer types, and SND1 has been
identified as a MTDH-binding protein that possesses tumor-pro-
moting functions similar to MTDH (Emdad et al., 2013; Wan and
Kang, 2013; Wan et al., 2014). However, the structural basis and
functional significance of the MTDH-SND1 interaction remain
unclear. The studies in this report mapped the minimal interac-
tion motif/domain of MTDH and SND1 and determined the
high-resolution crystal structure of their complex. Structural
analysis and structure-guided functional studies showed that
the MTDH-SND1 interface is essential for MTDH and SND1’s
activities in mammary tumor initiation and harbors structural
features with promise as potential cancer therapeutic targets.
In addition, the structure of the MTDH-SND1 complex provides
an important platform for future understanding of cancer cell
signaling bridged by this interaction.
The MTDH-SND1 interface characterized in this study pro-
vides key insights into the molecular basis of their interaction.
The essential SND1-binding motif was previously mapped to
two different regions of MTDH, residues 364–470 (Blanco
et al., 2011) and 101–205 (Yoo et al., 2011). Our study here
defined a short 11 residue peptide motif (residues 393–403) of
MTDH as the primary SND1-binding motif, which is located
within the fragment identified by Blanco et al. (2011). Mutations
in either MTDH or SND1 at this interface abolish the interaction
of the full-length proteins both in HEK293T cells and in breast
tumor cells, supporting the notion that this interface is the domi-
nant binding site between MTDH and SND1.
The prominent function of theMTDH-SND1 interface in cancer
promotion suggests that targeting this interface might be a use-
ful strategy for cancer therapy. In addition, our results suggest
important ways for targeting this interface. The interaction be-
tweenMTDH and SND1 is dominated by van der Waals contacts
between W394 and W401 in MTDH and two well-defined hydro-
phobic pockets in SND1 that have the potential to bind small
molecule inhibitors. Importantly, mutations in MTDH or SND1
at either binding pocket abolished their activity in promotion of
mammary tumor initiation, thus making simultaneously targeting
both SND1 pockets an attractive therapeutic approach. Other
appealing features of this interface for targeting include the
readily reversible binding betweenMTDH and SND1, suggesting
that this interaction could be reversed by specific inhibitors.
Furthermore, the MTDH-binding pockets are uniquely evolved
in SN1/2 domains, but absent in other OB-fold superfamily pro-
teins or other SN domains in SND1, underscoring the promise
of developing highly specific compounds for blocking MTDH
binding.
Such weak interactions are crucial for many important biolog-
ical processes. For example, the weak interactions between
protein phosphatase 2A (PP2A) and its phosphatase activator
(PTPA) dictate a robust chaperone function of PTPA in PP2A
activation (Guo et al., 2014). The transient recognition of herpes-
virus-associated ubiquitin-specific protease (HAUSP) and its
substrates p53 andMDM2 is crucial for deubiquitination of these
important signaling proteins (Hu et al., 2006). Recognition of
T cell receptors (TCRs) for peptides presented by major histo-Cell Recompatibility complex is also dictated by weak interactions
(Birnbaum et al., 2014). Similar to our study here, the strategy
of flexible fusion linkers to stabilize weak protein complexes
had been utilized for crystallization of these complexes (Birn-
baum et al., 2014; Guo et al., 2014; Hu et al., 2006). Recently,
the structure of the AcrAB-TolC multidrug efflux pump was re-
ported, where several flexible linkers were applied to stabilize
the complex and facilitate crystallization (Du et al., 2014).
The structure of the MTDH-SND1 interface provides an im-
portant platform for understanding the cellular signaling coordi-
nated by this interaction. Despite the structural similarity
between SN1/2 and SN3/4 domains, SN3/4 does not possess
the unique pockets and surface feature required for MTDH
binding. The binding pocket for W401 harbors residues with
multiple rotamers, where the van der Waals contact between
W401A mutation and this pocket may be partially compensated
by different side-chain conformations of these residues. In
contrast, the binding pocket for W394 is formed by three proline
residues, and its backbone structure could barely change the
conformation to compensate for alteration at 394 of MTDH (Fig-
ure 2B, electrostatic potential). Furthermore, the hilly surfaces
harboring protruding structures in SN1/2 and SN3/4 are
distinctly different and are expected to confer different binding
specificities. The domains in SND1 fragment containing SN3/
4-TSN5 domains are arranged in a linear orientation with a
crescent shape (Li et al., 2008) (Figure 5B). FRET analysis indi-
cated that the distance between the termini of the full-length
SND1 is farther than that of the SN3/4-TSN5 fragment (data
not shown), suggesting that the multiple SND1 domains are
arranged in a linear fashion (Figure 5B). This architecture likely
allows different binding partners to be orchestrated in a
coherent orientation for downstream signaling. Surprisingly,
MTDH associates via a short peptide to a surface of SND1
that is rather flat and distinctly different from the hilly surface
located on the opposite side of SND1. This simple mode of
binding is in sharp contrast to the robust function of this inter-
face in cancer promotion, suggesting that downstream signaling
mediated by this interface might contribute to the multifaceted
roles of MTDH and SND1 in cancer. Besides a single transmem-
brane domain, the entire 582 amino acid sequence of MTDH
is largely disordered, suggesting the possibility that MTDH
may interact with many signaling proteins. These features
resemble signaling scaffold proteins, such as AKAPs (a kinase
anchor protein; Gelman, 2012), suggesting that MTDH might
function as a signaling scaffold protein. Together with SND1,
MTDH might mediate cellular signaling via diverse signaling
molecules orchestrated by the multiple interaction domains/
motifs of SND1 and MTDH.
The reliance of SND1 stability on MTDH binding under stress
provides another explanation for the role of MTDH-SND1 inter-
action in cancer. This result is also consistent with the observa-
tion that MTDH and SND1 are simultaneously elevated in tumor
tissues (Wan et al., 2014; Wang et al., 2012). How the MTDH-
SND1 interaction contributes to SND1 stability under stress,
however, remains to be determined. Our in vitro study demon-
strated that MTDH binding barely affects the thermal stability
of SN1/2 domains or their sensitivity to protease cleavage
(data not shown), suggesting that MTDH binding might notports 8, 1704–1713, September 25, 2014 ª2014 The Authors 1711
directly stabilize SND1. Further studies are needed to decipher
whether the cellular stability of SND1 relies on recruitment of
other biomolecules.
EXPERIMENTAL PROCEDURES
Crystallization, Data Collection, and Structure Determination
Crystals of SND1 and MTDH fusion protein were grown at 20C using the
sitting-drop vapor-diffusion method by mixing 250 nl of 15 mg/ml SeMet-
labeled SND1(16–339)-L21-MTDH (386–407) with 250 nl of well buffer
(21.6% pEG3350, 0.1M sodium citrate [pH 8.0], 0.1M CsCl), plus 50 nl of micro
seeds. Single crystals grew in 4 days and matured after 7 days. Crystals were
gradually changed to well buffer with 0%–25% glycerol before being flash
frozen in liquid nitrogen. A SAD data set useful for structure determination
was collected and processed to 2.7 A˚. X-ray diffraction data collection and
structure determination are described in Supplemental Experimental Proce-
dures. The final structure was refined to 2.7 A˚ (Table S1). Structural analysis,
calculation of electrostatic potential, and structural presentation were per-
formed using the program ccp4mg (McNicholas et al., 2011).
Tumorsphere and Tumorigenesis Assays
For tumorsphere analysis, single cells were plated in ultra-low attachment
plates (Corning) with sphere media (1:1 DMEM: Ham’s 12 supplemented
with B27 (Invitrogen), 20 ng/ml EGF, 20 ng/ml basic fibroblast growth factor,
and 4 mg/ml heparin). Spheres were counted 4–7 days after plating. For
tumorigenesis assays, indicated numbers of PyMT tumor cells were trans-
planted into mammary fat of FVB recipient mice and tumor formations were
monitored twice every week. Tumors were considered established when
they became palpable for two consecutive weeks, and tumor size was
measured by calipers for calculation of tumor volumes (p 3 length 3
width2/6). All procedures involving mice and all experimental protocols
were approved by Institutional Animal Care and Use Committee (IACUC)
of Princeton University. Statistical analysis is described in Supplemental
Experimental Procedures.
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The atomic coordinates of the MTDH-SND1 complex were deposited in the
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